The Review opens with a central clinical observation: excess adiposity does not produce a uniform metabolic signature. Investigators reported that multi-organ insulin resistance is the dominant pathogenic process driving many obesity-related complications, yet insulin sensitivity varies substantially among people with obesity. Some individuals meet criteria for metabolically healthy obesity, defined by preserved insulin sensitivity and normal fasting blood glucose, oral glucose tolerance, plasma lipid measures and intrahepatic triglyceride content. Other people with similar degrees of adiposity show the full spectrum of dysmetabolism — dyslipidemia, impaired glycaemic regulation, and fatty liver disease.
The article includes a schematic figure that maps heterogeneity in insulin sensitivity among people without diabetes. That figure is a descriptive aid rather than a numeric prevalence statement in the accessible preview; the Review later presents an estimated percentage split between metabolically healthy and unhealthy cohorts in a separate figure, but numeric ranges were not included in the preview text available here.
Authors contrast differences at multiple biological levels. At the cellular level, prior literature and the Review point to distinct adipocyte function and local inflammatory states as factors that differentiate metabolic phenotypes. Organ-system differences include divergent hepatic lipid accumulation and lipid handling, variable skeletal muscle insulin action, and altered adipose tissue capacity to store triglyceride safely. The study team observed that these organ-level processes — taken together — determine systemic metabolic homeostasis.
The Review discusses circulating biomarkers and interorgan signalling pathways reported in the literature as mediators of metabolic divergence, including adipokines and lipid fluxes, but the accessible summary does not provide new biomarker datasets. Where the authors summarise mechanistic evidence, they rely on previously published human and translational studies rather than reporting novel primary data within this Review.
The article incorporates a figure depicting 24-h metabolic profiles in metabolically healthy versus metabolically unhealthy people with obesity. That visual compares glucose, insulin and lipid-related rhythms across a day, reflecting different postprandial and fasting dynamics between groups. The Review also presents schematic models to explain how adipose tissue dysfunction could propagate insulin resistance across organs.
Those schematic representations serve to organise complex, multi-tissue biology for clinicians and researchers. The accessible preview shows the figures but does not include underlying raw traces or detailed quantitative descriptions; readers seeking exact profile data must consult the full text.
The authors address how people with divergent metabolic phenotypes respond variably to weight-loss interventions. Data from prior trials and observational studies — which the Review synthesises — indicate that the metabolic benefits of weight reduction are not uniform: some individuals experience marked improvements in insulin sensitivity and liver fat, whereas others have more modest metabolic change despite similar weight loss. The Review notes heterogeneity in therapeutic effects but the preview does not provide specific intervention protocols, magnitudes of change, or subgroup effect sizes.
This section stresses that understanding phenotype-specific responses could help clinicians personalise treatment plans and predict which patients will obtain metabolic benefit from particular weight-loss strategies. The Review summarises the literature rather than reporting new interventional trial outcomes.
The authors summarise conceptual models that link adipose tissue characteristics to systemic metabolic dysfunction. Figures in the Review outline mechanisms such as impaired adipose triglyceride storage capacity, ectopic lipid deposition, altered adipokine secretion and low-grade inflammation as plausible drivers of cross-organ insulin resistance. The Review organises evidence from cellular, animal and human studies into mechanistic frameworks meant to clarify pathways connecting adipose pathology with hepatic, muscular and cardiovascular metabolic disturbances.
These models are presented as integrative hypotheses supported by cited literature; the accessible preview contains the schematics but does not supply new experimental validation within the Review itself.
The previewed Review is a synthesis of existing literature rather than a primary data report. The authors did not present new trial-level numbers or novel experimental datasets in the accessible abstract and figures. Specific numeric prevalence ranges, stratified outcome data, and intervention dosing or protocol details were not reported in the preview text and require access to the full article.
Open questions listed or implied by the authors include: what precise biological determinants establish long-term metabolic resilience in people with obesity; which patient features best predict durable metabolic improvement after weight loss; and how to translate mechanistic models into phenotype-targeted therapies. The Review compiles current evidence and models but leaves these actionable clinical questions for future empirical study and for clinicians to assess in the context of the broader literature.